IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 601–700 of 1,012

1. Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors
   Andrea Morandi, Maria Letizia Taddei, Paola Chiarugi, Elisa Giannoni · 2017 · Frontiers in Oncology
2. Metabolomic Analysis of Bone Morphogenetic Protein Receptor Type 2 Mutations in Human Pulmonary Endothelium Reveals Widespread Metabolic Reprogramming
   Joshua P. Fessel, Rizwan Hamid, Bryan M. Wittmann, Linda J. Robinson, Tom Blackwell, Yuji Tada, Nobuhiro Tanabe, Koichiro Tatsumi, Anna Ryan Hemnes, James D. West · 2012 · Pulmonary Circulation
3. Cysteine Catabolism: A Novel Metabolic Pathway Contributing to Glioblastoma Growth
   Antony Herold Prabhu, Bhaswati Sarcar, Soumen Kahali, Zhigang Yuan, Joseph Johnson, Klaus‐Peter Adam, Elizabeth Kensicki, Prakash Chinnaiyan · 2013 · Cancer Research
4. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1
   Tali Mazor, Charles Chesnelong, Aleksandr Pankov, Llewellyn E. Jalbert, Chibo Hong, Josie L. Hayes, Ivan V. Smirnov, Roxanne E. Marshall, Camila Ferreira de Souza, Yaoqing Shen et al. · 2017 · Proceedings of the National Academy of Sciences
5. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
   Claire L. Green, Catherine M. Evans, Robert Kerrin Hills, Alan K. Burnett, David C. Linch, Rosemary E. Gale · 2010 · Blood
6. Retracted: A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas
   Chandan Ganesh Bangalore Yogananda, Bhavya Shah, Maryam Vejdani‐Jahromi, Sahil Sunil Nalawade, Gowtham Krishnan Murugesan, Frank F. Yu, Marco C. Pinho, Benjamin Wagner, Bruce Mickey, Toral Patel et al. · 2019 · Neuro-Oncology · Retracted
7. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
   Jayson Bastien, Katharine Anne McNeill, Howard Alan Fine · 2014 · Cancer
8. Lower Grade Gliomas
   Gilbert Youssef, Julie J. Miller · 2020 · Current Neurology and Neuroscience Reports
9. Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China
   Wei Yan, Wei Zhang, Gan You, Zhaoshi Bao, Yongzhi Wang, Yanwei Liu, Chunsheng Kang, Yongping You, Lei Wang, Tao Jiang · 2012 · PLoS ONE
10. O-GlcNAc signaling in cancer metabolism and epigenetics
    Jay Prakash Singh, Kaisi Zhang, Jing Wu, Xiaoyong Yang · 2014 · Cancer Letters
11. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma
    Jingwen Jiang, Lu Zhang, Hai‐Ning Chen, Yunlong Lei, Tao Zhang, Yuelong Wang, Ping Jin, Jiang Lan, Li Zhou, Zhao Huang et al. · 2019 · Autophagy
12. Advances in histone demethylase KDM4 as cancer therapeutic targets
    Dong Hoon Lee, Go Woon Kim, Yu Hyun Jeon, Jung Hoan Yoo, Sang Wu Lee, So Hee Kwon · 2020 · The FASEB Journal
13. Organic Bioelectronic Devices for Metabolite Sensing
    Anil Koklu, David Ohayon, Shofarul Wustoni, Victor Druet, Abdulelah Saleh, Sahika Inal · 2021 · Chemical Reviews
14. IDH1andIDH2Mutations in Gliomas
    Emilie De Carli, Xiao-Wei Wang, S. Puget · 2009 · New England Journal of Medicine
15. Performance of Common Analysis Methods for Detecting Low-Frequency Single Nucleotide Variants in Targeted Next-Generation Sequence Data
    David H. Spencer, Manoj G Tyagi, Francesco Vallania, Andrew J. Bredemeyer, John D. Pfeifer, Robi David Mitra, Eric James Duncavage · 2013 · Journal of Molecular Diagnostics
16. IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
    Sarah Chiang, Britta Weigelt, Huei‐Chi Wen, Fresia G. Pareja, Ashwini Raghavendra, Luciano Gastón Martelotto, Kathleen A. Burke, Thais Basili, Anqi Li, Felipe Correa Geyer et al. · 2016 · Cancer Research
17. Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas
    Sen Liang, Rongguo Zhang, Dayang Liang, Tianci Song, Tao Ai, Xia Chen, Liming Xia, Yan Wang · 2018 · Genes
18. Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment
    Barrie Peck, Almut Schulze · 2019 · Trends in cancer
19. Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51
    Thomas Backus Daniels, Paul D. Brown, Sara J. Felten, Wenting Wu, Jan C. Buckner, Robert M. Arusell, Walter John Curran, Ross Allen Abrams, David Schiff, Edward G. Shaw · 2011 · International Journal of Radiation Oncology*Biology*Physics
20. Neuronal-Astrocyte Metabolic Interactions: Understanding the Transition Into Abnormal Astrocytoma Metabolism
    Dennis A. Turner, David Cory Adamson · 2011 · Journal of Neuropathology & Experimental Neurology
21. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers
    Min Sung Kim, Soo Young Hur, Nam Jin Yoo, Sug Hyung Lee · 2010 · The Journal of Pathology
22. The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype
    Francesca De Bacco, Elena Casanova, Enzo Médico, Serena Pellegatta, Francesca Orzan, Raffaella Albano, Paolo Luraghi, Gigliola Reato, Antonio D'Ambrosio, Paola Porrati et al. · 2012 · Cancer Research
23. Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
    Jun-Rui Chen, Yu Yao, Hongzhi Xu, Zhiyong Qin · 2016 · Medicine
24. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course
    Annika K. Wefers, Damian Stichel, Daniel Schrimpf, Roland Coras, Mélanie Pagès, Arnault Tauziède‐Espariat, Pascale Varlet, Daniel F. Schwarz, Figen Söylemezoğlu, Ute Pohl et al. · 2019 · Acta Neuropathologica
25. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis
    Sabine Spiegl‐Kreinecker, Daniela Lötsch, Bahil Ghanim, Christine Pirker, Thomas T. Mohr, Magdalena Laaber, Serge Weis, A Olschowski, Gerald Webersinke, Josef Pichler et al. · 2015 · Neuro-Oncology
26. Metabolic Reprogramming in Brain Tumors
    Sriram Venneti, Craig B. Thompson · 2017 · Annual Review of Pathology Mechanisms of Disease
27. DNA methylation-based classification of sinonasal undifferentiated carcinoma
    Snjezana Doğan, Varshini Vasudevaraja, Bin Xu, Jonathan Serrano, Ryan N. Ptashkin, Hun Jae Jung, Sarah Chiang, Achim A. Jungbluth, Marc A. Cohen, Ian Ganly et al. · 2019 · Modern Pathology
28. Cancer and the Nervous System
    Michael Jansen, Arie Perry, Reid Russell Heffner, David N. Louis · 2012 · Elsevier eBooks
29. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
    Steven M. Chan, Ravindra Majeti · 2013 · International Journal of Hematology
30. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology
    David Capper, David Reuß, Jens Schittenhelm, Christian Johannes Hartmann, Juliane Bremer, Felix Sahm, Patrick N. Harter, Astrid Jeibmann, Andreas von Deimling · 2010 · Acta Neuropathologica
31. Molecular pathogenesis of IDH mutations in gliomas
    Koichi Ichimura · 2012 · Brain Tumor Pathology
32. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
    Lipika Goyal, Aparna Govindan, Rahul A. Sheth, Valentina Nardi, Lawrence Scott Blaszkowsky, Jason Edward Faris, Jeffrey William Clark, David P. Ryan, Eunice Lee Kwak, Jill N. Allen et al. · 2015 · The Oncologist
33. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing
    Shipra Agarwal, Mehar Chand Sharma, Pankaj Jha, Pankaj Pathak, Vaishali S. Suri, Chitra Sarkar, Kunzang Chosdol, A. Suri, Shashank Sharad Kale, A. K. Mahapatra et al. · 2013 · Neuro-Oncology
34. Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors
    Andrew David Miller, C. Ryan Miller, John Henry Rossmeisl · 2019 · Frontiers in Oncology
35. Advances in the management of glioblastoma
    Ruichong Ma, MARTIN J.B. TAPHOORN, Puneet Plaha · 2021 · Journal of Neurology Neurosurgery & Psychiatry
36. IDH mutations in acute myeloid leukemia
    Dinesh Rakheja, Sergej Naumovich Konoplev, Leonard Jeffrey Medeiros, Weina Chen · 2012 · Human Pathology
37. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer
    Avaniyapuram Kannan Murugan, Ermal Bojdani, Mingzhao Xing · 2010 · Biochemical and Biophysical Research Communications
38. Metabolic alterations in cancer cells and therapeutic implications
    Naima Hammoudi, Kausar Begam Riaz Ahmed, Celia Garcı́a-Prieto, Peng Huang · 2011 · 癌症：英文版
39. Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
    Tatsuhiro Shibata, Akiko Kokubu, Masashi Miyamoto, Yuko Sasajima, Naoya Yamazaki · 2011 · American Journal Of Pathology
40. Advances in epigenetic therapeutics with focus on solid tumors
    Ning Yi Jin, Tiffany L. George, Gregory A. Otterson, Claire F. Verschraegen, Haitao Wen, David Paul Carbone, James Gordon Herman, Erin Marie Bertino, Kai He · 2021 · Clinical Epigenetics
41. Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine
    Sanjay Saxena, Biswajit Jena, Neha Gupta, Suchismita Das, Deepaneeta Sarmah, Pallab Bhattacharya, Tanmay Nath, Sudip Paul, Mostafa M. Fouda, Manudeep K. Kalra et al. · 2022 · Cancers
42. T cell exhaustion in malignant gliomas
    Matthew Watowich, Mark R. Gilbert, Mioara Larion · 2023 · Trends in cancer
43. 2-Hydroxyglutarate in Cancer Cells
    Ježek, Petr · 2020 · Antioxidants & Redox Signaling
44. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
    Tor-Christian Aase Johannessen, Rolf Bjerkvig · 2012 · Expert Review of Anticancer Therapy
45. e-Driver: a novel method to identify protein regions driving cancer
    Eduard Porta‐Pardo, Adam Godzik · 2014 · Bioinformatics
46. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
    Chunzhi Zhang, Lynette M. Moore, Xia Li, W. K. Alfred Yung, Wei Zhang · 2013 · Neuro-Oncology
47. Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma
    Stephen C. Mack, Irtisha Singh, Xiuxing Wang, Rachel A. Hirsch, Quilian Wu, Rosie Villagomez, Jean A. Bernatchez, Zhe Zhu, Ryan C. Gimple, Leo J.Y. Kim et al. · 2019 · The Journal of Experimental Medicine
48. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect
    Xiang, Shaoxun, Gu, Hao, Jin, Lei, Thorne, Rick F., Zhang, Xu Dong, Wu, Mian · 2018 · Proceedings of the National Academy of Sciences
49. Oncogenic extracellular vesicles in brain tumor progression
    Esterina D’Asti, Delphine Garnier, Tae Hoon Lee, Laura Montermini, Brian Meehan, Janusz W. Rak · 2012 · Frontiers in Physiology
50. Diffuse intrinsic pontine gliomas—current management and new biologic insights. Is there a glimmer of hope?
    Kenneth J. Cohen, Nada Jabado, Jacques Grill · 2017 · Neuro-Oncology
51. Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis
    Christos Chinopoulos, Thomas N. Seyfried · 2018 · ASN NEURO
52. The Janus-like role of proline metabolism in cancer
    L. E. Carol-Ann Burke, Inna Guterman, Raquel Palacios-Gallego, Robert G. Britton, D. Burschowsky, Cristina Tufarelli, Alessandro Rufini · 2020 · Cell Death Discovery
53. Hydrogel-Based Drug Delivery Nanosystems for the Treatment of Brain Tumors
    João Basso, Ana Miranda, Sandra C. C. Nunes, Tânia F. G. G. Cova, João Sousa, Carla Vitorino, Alberto A. C. C. Pais · 2018 · Gels
54. Extracellular vesicles as a platform for ‘liquid biopsy’ in glioblastoma patients
    David Rafael Santiago-Dieppa, Jeffrey D. Steinberg, David D. Gonda, Vincent J. Cheung, Bob S. Carter, Clark C. Chen · 2014 · Expert Review of Molecular Diagnostics
55. Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
    José Gaal, Nelly Burnichon, Esther Korpershoek, Isabelle Roncelin, Jerome Yves Bertherat, Pierre‐François Plouin, Ronald R. de Krijger, Anne‐Paule Gimenez‐Roqueplo, Winand N.M. Dinjens · 2009 · The Journal of Clinical Endocrinology & Metabolism
56. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007
    Robert Dubrow, Amy S. Darefsky · 2011 · BMC Cancer
57. Characterization of gliomas: from morphology to molecules
    Sean P. Ferris, Jeffrey W. Hofmann, David A. Solomon, Arie Perry · 2017 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
58. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
    Guanzhang Li, Zheng Wang, Chuanbao Zhang, Xing Liu, Jinquan Cai, Zhiliang Wang, Huimin Hu, Fan Wu, Zhaoshi Bao, Yanwei Liu et al. · 2017 · OncoImmunology
59. The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma
    Erik Ladomersky, Denise M. Scholtens, Masha Kocherginsky, Elizabeth A. Hibler, Elizabeth T. Bartom, Sebastian Otto‐Meyer, Lijie Zhai, Kristen L. Lauing, Jaehyuk Choi, Jeffrey Alan Sosman et al. · 2019 · Frontiers in Pharmacology
60. Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
    Zhong Lan, Xin Li, Xiaoqin Zhang · 2024 · International Journal of Molecular Sciences
61. STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
    Jennifer Kim, Mira A. Patel, Jacob Ruzevick, Christopher M. Jackson, Michael K. Lim · 2014 · Cancers
62. Multidimensional scaling of diffuse gliomas: Application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery
    Cimino, Patrick J., Zager, Michael, McFerrin, Lisa, Wirsching, Hans-Georg, Bolouri, Hamid, Hentschel, Bettina, von Deimling, Andreas, Jones, David, Reifenberger, Guido, Weller, Michael et al. · 2017 · Acta Neuropathologica Communications
63. Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
    Meena Jhanwar‐Uniyal, Michael LaBagnara, Marissa Friedman, Amanda M. Kwasnicki, Raj Murali · 2015 · Cancers
64. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
    Hamoud Al‐Khallaf · 2017 · Cell & Bioscience
65. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus
    David Schiff, Martin J. van den Bent, Michael A. Vogelbaum, Wolfgang Wick, C. Ryan Miller, MARTIN J.B. TAPHOORN, Whitney B. Pope, Paul D. Brown, Michael Platten, Rakesh Jalali et al. · 2019 · Neuro-Oncology
66. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning
    Sidong Liu, Zubair Shah, Aydın Sav, Carlo Russo, Shlomo Berkovsky, Yi Qian, Enrico W Coiera, Antonio Di Ieva · 2020 · Scientific Reports
67. NF-κB and STAT3 signaling in glioma: targets for future therapies
    George P. Atkinson, Susan E. Nozell, Etty N. Benveniste · 2010 · Expert Review of Neurotherapeutics
68. Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma
    Pawel Buczkowicz, Cynthia E Hawkins · 2015 · Frontiers in Oncology
69. Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth
    Luca Lignitto, Antonietta Arcella, Maria Sepe, Laura Rinaldi, Rossella Delle Donne, Adriana Gallo, Eduard Stefan, Verena A. Bachmann, Maria Antonietta Oliva, Clelia Tiziana Storlazzi et al. · 2013 · Nature Communications
70. Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
    Genglin Jin, Zachary J. Reitman, Christopher G. Duncan, Ivan Spasojević, David M. Gooden, B. Ahmed Rasheed, Rui Ryan Yang, Giselle Yvette Lopez, Yiping He, Roger E. McLendon et al. · 2012 · Cancer Research
71. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
    Michael J. Karsy, Jian Guan, Adam Louis Cohen, Randy L. Jensen, Howard Colman · 2017 · Current Neurology and Neuroscience Reports
72. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
    Young Shin Cho, Julian R. Levell, Gang Liu, Thomas R. Caferro, James C. Sutton, Cynthia M. Shafer, Abran Costales, James R. Manning, Qian Lei Zhao, Martin Sendzik et al. · 2017 · ACS Medicinal Chemistry Letters
73. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations
    Rui Ryan Yang, Zhifeng Shi, Zhen‐yu Zhang, Aden Ka‐Yin Chan, Abudumijiti Aibaidula, Weiwei Wang, Johnny S. H. Kwan, Wai Sang Poon, Hong Chen, Wencai Li et al. · 2019 · Brain Pathology
74. SIRT2‐dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases
    Bo Wang, Yingjiang Ye, Xin Ping Yang, Boya Liu, Zhe Wang, Shuaiyi Chen, Kewei Jiang, Wei Zhang, Hongpeng Jiang, Harri K. Mustonen et al. · 2020 · EMBO Reports
75. D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization
    Böttcher, Martin, Renner, Kathrin, Berger, Raffaela, Mentz, Kristin, Thomas, Simone, Cardenas-Conejo, Zugey Elizabeth, Dettmer, Katja, Oefner, Peter J., Mackensen, Andreas, Kreutz, Marina et al. · 2018 · OncoImmunology
76. Deregulation of cell signaling in cancer
    Filippo G. Giancotti · 2014 · FEBS Letters
77. Treatment options and outcomes for glioblastoma in the elderly patient
    David A. Reardon, Nils D. Arvold · 2014 · Clinical Interventions in Aging
78. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells
    Philippe Icard, Hubert Lincet · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
79. Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients
    Robert Michael Prins, Xiaoyan Wang, Horacio Soto, Emma Young, Dominique N. Lisiero, Brendan Fong, Richard G. Everson, William H. Yong, Albert Lai, Gang� Li et al. · 2013 · Journal of Immunotherapy
80. Hypoxia-inducible factors in cancer stem cells and inflammation
    Gong Peng, Yang Liu · 2015 · Trends in Pharmacological Sciences
81. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
    Mohamed Ali Mosrati, Annika Malmström, M Łysiak, Adam Krysztofiak, Martin Hallbeck, Peter Milos, Anna‐Lotta Hallbeck, Charlotte Bratthäll, Michael Strandéus, Marie Stenmark‐Askmalm et al. · 2015 · Oncotarget
82. Novel Delivery Strategies for Glioblastoma
    Jiangbing Zhou, Kofi‐Buaku Atsina, Benjamin T. Himes, Garth William Strohbehn, W. Mark Saltzman · 2012 · The Cancer Journal
83. Role of AHR and HIF-1α in Glioblastoma Metabolism
    Galina Gabriely, Michael A. Wheeler, Maisa C. Takenaka, Francisco Javier Quintana · 2017 · Trends in Endocrinology and Metabolism
84. Noninvasive Assessment ofIDHMutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging
    Zhen Xing, Xiefeng Yang, Dejun She, Yu Lin, Yuyang Zhang, Dairong Cao · 2017 · American Journal of Neuroradiology
85. A chemoproteomic portrait of the oncometabolite fumarate
    Rhushikesh A. Kulkarni, Daniel W. Bak, Darmood Wei, Sarah E. Bergholtz, Chloe A. Briney, Jonathan H. Shrimp, Aktan Alpsoy, Abigail L. Thorpe, Arissa E. Bavari, Daniel R. Crooks et al. · 2019 · Nature Chemical Biology
86. ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas
    David Gomez‐Zepeda, Méryam Taghi, Jean‐Michel Scherrmann, Xavier Declèves, Marie‐Claude Menet · 2019 · Pharmaceutics
87. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis
    Christian Mirian, Anne Katrine Duun‐Henriksen, Tareq Adnan Juratli, Felix Sahm, Sabine Spiegl‐Kreinecker, Matthieu Peyre, Annamaria Biczok, Jörg‐Christian Tonn, Stéphane Goutagny, Luca Bertero et al. · 2020 · Journal of Neurology Neurosurgery & Psychiatry
88. An integrative analysis of the age-associated multi-omic landscape across cancers
    Kasit Chatsirisupachai, Tom Lesluyes, Luminita Paraoan, Peter Van Loo, João Pedro de Magalhães · 2021 · Nature Communications
89. Glutamine Metabolism in Cancer
    Ting Li, Christopher Copeland, Anne Le · 2021 · Advances in experimental medicine and biology
90. Demographic bias in misdiagnosis by computational pathology models
    Anurag Jayant Vaidya, Richard J. Chen, Drew F. K. Williamson, Andrew H. Song, Guillaume Jaume, Yuzhe Yang, Thomas Hartvigsen, Emma Dyer, Ming Y. Lu, Jana Lipková et al. · 2024 · Nature Medicine
91. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
    Serena Pellegatta, Lorella Valletta, Cristina Corbetta, Monica Patanè, Ileana Zucca, Federico Riccardi Sirtori, Maria Grazia Bruzzone, Gianpaolo Fogliatto, Antonella Isacchi, Bianca Pollo et al. · 2015 · Acta Neuropathologica Communications
92. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
    Anuhar Chaturvedi, Lena Herbst, Stefan Pusch, Lara C. Klett, Ramya Goparaju, Damian Stichel, Silke Kaulfuß, Olaf Panknin, Katja C. Zimmermann, Luisella Toschi et al. · 2017 · Leukemia
93. Malignant Glioma
    Linda M. Wang, Zachary K. Englander, Michael L. Miller, Jeffrey N. Bruce · 2023 · Advances in experimental medicine and biology
94. Autophagy, Stress, and Cancer Metabolism: What Doesn't Kill You Makes You Stronger
    R. Mathew, Eileen White · 2011 · Cold Spring Harbor Symposia on Quantitative Biology
95. Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia
    Jumpei Yamazaki, Rodolphe F. Taby, Aparna Vasanthakumar, Trisha A. Macrae, Kelly R. Ostler, Lanlan Shen, Hagop M. Kantarjian, Marcos R. Estecio, Jaroslav Jelı́nek, Lucy A. Godley et al. · 2012 · Epigenetics
96. Alterations of metabolic genes and metabolites in cancer
    Eric Karl Oermann, Jing Wu, Kun‐Liang Guan, Yue Xiong · 2012 · Seminars in Cell and Developmental Biology
97. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
    Amir T. Fathi, Hossein Sadrzadeh, Darrell R. Borger, Karen Kuhn Ballen, Philip C. Amrein, Eyal C. Attar, Julia Foster, Meghan E. Burke, Hector U. Lopez, Christina R. Matulis et al. · 2012 · Blood
98. Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets
    Elena Codrici, Ana‐Maria Enciu, Ionela Daniela Popescu, Simona Mihai, Cristiana Tănase · 2016 · Stem Cells International
99. Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
    Vera Miranda‐Gonçalves, Ana Lameirinhas, Rui Henrique, Cármen Jerónimo · 2018 · Frontiers in Genetics
100. Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT)
     Alexandra R. Grassian, Fallon Lin, Rosemary Barrett, Yue Liu, Wei Jiang, Manav Korpal, Holly M. Astley, Daniel P. Gitterman, Thomas Henley, Rob Howes et al. · 2012 · Journal of Biological Chemistry